Our data presented in the present report are consistent with the potential of a dual inhibitor of Hh and TGF-β signaling, for example, Oxy210, as a therapy for lung fibrosis and perhaps other fibrotic diseases. This evidence concerns the gene TGFB1 and pulmonary fibrosis.